Related Experiment Video
Updated: Jun 18, 2026

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
Published on: August 24, 2018
Metabolic alterations during valproic acid treatment: a prospective study
Ayhan Abaci1, Murat Saygi, Uluc Yis
1Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey.
Insights
Valproic acid treatment in epileptic children significantly increased body mass index and cholesterol levels, raising concerns for obesity. Regular monitoring for weight gain and metabolic changes is recommended during therapy.
Area of Science:
- Pediatric Endocrinology
- Clinical Neurology
- Metabolic Disorders
Background:
- Epilepsy is a common neurological disorder in children.
- Valproic acid is a widely used antiepileptic drug.
- Potential endocrine and metabolic side effects of valproic acid require investigation.
Purpose of the Study:
- To prospectively evaluate the impact of valproic acid on endocrine and metabolic variables in children with newly diagnosed epilepsy.
- To assess changes in body mass index, glucose metabolism, lipid profiles, and hormone levels during valproic acid treatment.
Main Methods:
- Prospective study involving 30 children with newly diagnosed idiopathic epilepsy.
- Assessment of clinical and laboratory variables at baseline, 6 months, and 12 months of valproic acid treatment.
- Measurements included body mass index, glucose, insulin, lipid profiles, and androgen hormones.
Main Results:
- Significant increases in body mass index and body mass index standard deviation scores were observed during treatment.
- Total and low-density lipoprotein cholesterol levels significantly increased after 12 months.
- A correlation was found between serum valproic acid levels and body mass index at 6 months.
- No significant changes in fasting glucose, insulin, triglycerides, HDL, or androgens in prepubertal children.
Conclusions:
- Valproic acid treatment is associated with weight gain and dyslipidemia in epileptic children.
- Increased risk of overweight and obesity necessitates regular monitoring.
- Further research into the long-term metabolic consequences is warranted.
Abstract:
We prospectively examined the effects of valproic acid on the endocrine system and metabolic variables in epileptic children. Patients with newly diagnosed idiopathic epilepsy were included in the study. Laboratory and clinical variables were assessed before and after 6 and 12 months of treatment. In total, 30 patients (mean age, 8.6 +/- 4.4 years S.D.) were investigated. Body mass index and body mass index standard deviation scores of patients increased significantly during treatment. Although there was no statistical significance regarding fasting glucose, serum insulin, triglyceride, and high-density lipoprotein cholesterol levels and the insulin resistance index, a statistically significant increase in total and low-density lipoprotein cholesterol levels had occurred after 12 months of valproic acid treatment. At the end of the study period, four patients were obese, and six patients were overweight. There was a significant correlation between serum levels of valproic acid and body mass index at month 6 of treatment. There was no significant change in androgen hormone levels during treatment in the prepubertal group. Body mass index and body mass index standard deviation scores increased during the first 6 months of valproic acid treatment. Patients treated with valproic acid should be regularly followed for obesity.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Bioavailability Study Design: Healthy Subjects Versus Patients
